MacuLogix Company

MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order to prevent vision loss.
Technology: P4 Medicine
Industry: Health Care, Health Diagnostics, Therapeutics
Headquarters: Harrisburg, Pennsylvania, United States
Founded Date: 1-1
Employees Number: 51-100
Funding Status: Late Stage Venture
Investors Number: 11
Total Funding: $151M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Equity

Visit Website
info@maculogix.com
https://twitter.com/maculogix
Register and Claim Ownership